Deerfield Management Company, L.P. (Series C) Revolution Medicines, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,650,342 shares of RVMD stock, worth $247 Million. This represents 3.17% of its overall portfolio holdings.
Number of Shares
3,650,342
Previous 3,384,072
7.87%
Holding current value
$247 Million
Previous $125 Million
36.92%
% of portfolio
3.17%
Previous 2.86%
Shares
15 transactions
Others Institutions Holding RVMD
# of Institutions
357Shares Held
195MCall Options Held
2.66MPut Options Held
945K-
Vanguard Group Inc Valley Forge, PA15.7MShares$1.06 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA14.6MShares$991 Million2.96% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$908 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.4MShares$769 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA9.81MShares$665 Million0.08% of portfolio
About Revolution Medicines, Inc.
- Ticker RVMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,697,600
- Market Cap $5.94B
- Description
- Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...